Far Infrared Irradiation for Managing, Control and Treatment of Huntington's Disease (HD)

GAAD Medical Research Institute Inc.

Status and phase: Unknown; Phase 1

Conditions: Huntington Disease

Treatments: Radiation: Far Infrared Radiation

Study type: Interventional

Funder types: Other

Identifiers

NCT00675077

GAAD-HD-CTP1

Details and patient eligibility

About

Huntington's disease (HD) is a fatal disease with profound neurological and behavioral features. HD is typically characterized by uncontrollable movements and psychological disturbances.

This study will investigate the use of far infrared radiation for control, management and treatment of HD.

Full description

Observations from our research studies indicate that, far infrared rays provide energy to the body, improve the autonomic functions of the nervous system, restore the functions of the endocrine system, strengthen the immune system, improve blood circulation and increase the level of oxygen in the cells and promote the regeneration of muscle cells, nerves and brain cells.

It is hereby postulated that irradiation using far infrared, with wavelength between 5 to 20 microns, of the central nervous system, the endocrine system and the whole body could prevent, control, manage or possibly lead to complete rehabilitation of people who have HD.

Enrollment: 5 estimated patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• People with HD

Exclusion criteria

• None

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)

---

5 participants in 1 patient group

1

Experimental group

Description:

Radiation: Far Infrared Radiation (5μm to 20μm wavelength)

Treatment:

Radiation: Far Infrared Radiation